<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826485</url>
  </required_header>
  <id_info>
    <org_study_id>PRIC</org_study_id>
    <nct_id>NCT03826485</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Crossover Study to Compare Pharmacokinetics of PRIC and Pranlukast Dry Syrup in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SamA Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SamA Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is Safety, Pharmacokinetic Study of PRIC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To Compare Pharmacokinetics of PRIC and Pranlukast Dry Syrup

        2. To evaluate the safety and tolerability of PRIC and Pranlukast Dry Syrup
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) to last time point (t)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10 and 12hours postdose</time_frame>
    <description>Area under the PRIC/Pranlukast dry syrup concentration in blood-time curve from zero to the final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of drug (Cmax)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10 and 12hours postdose</time_frame>
    <description>The maximum PRIC/Pranlukast dry syrup concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: PRIC Period 2: Pranlukast hydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Pranlukast hydrate Period 2: PRIC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRIC</intervention_name>
    <description>Pranlukast hydrate 50mg</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
    <other_name>PRIC 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pranlukast hydrate</intervention_name>
    <description>Pranlukast hydrate 225mg/2.25g</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 to 45 years old healthy male subject at the screening

          -  Subject who is able to provide written informed consent and decided on his own
             participation after understanding fully to hear a detailed explanation in the clinical
             study

        Exclusion Criteria:

          -  Subject with hereditary diseases of galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption etc.

          -  Subjects with history of clinically significant allergy, cardiovascular, peripheral
             vascular, skin, mucocutaneous, ocular, ear, nose and throat (ENT), respiratory,
             musculoskeletal, infectious, gastrointestinal, liver, biliary, endocrine, renal,
             genitourinary, nervous, psychiatric, blood disorders, tumors, fractures or any other
             conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Hyung Suk Lim, MD, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pranlukast hydrate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pranlukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

